Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy.

Proteins bind the surfaces of nanoparticles, and biological materials in general, immediately upon introduction of the materials into a physiological environment. The further biological response of the body is influenced by the nanoparticle-protein complex. The nanoparticle's composition and surface chemistry dictate the extent and specificity of protein binding. Protein binding is one of the key elements that affects biodistribution of the nanoparticles throughout the body. Here we review recent research on nanoparticle physicochemical properties important for protein binding, techniques for isolation and identification of nanoparticle-bound proteins, and how these proteins can influence particle biodistribution and biocompatibility. Understanding the nanoparticle-protein complex is necessary for control and manipulation of protein binding, and allows for improved engineering of nanoparticles with favorable bioavailability and biodistribution.

[1]  S. Davis,et al.  The effect of surface coverage and conformation of poly(ethylene oxide) (PEO) chains of poloxamer 407 on the biological fate of model colloidal drug carriers. , 2001, Biochimica et biophysica acta.

[2]  Kristen M Kulinowski,et al.  Nanoparticles as catalysts for protein fibrillation , 2007, Proceedings of the National Academy of Sciences.

[3]  Jean-Christophe Olivier,et al.  Drug transport to brain with targeted nanoparticles , 2011, NeuroRX.

[4]  R. Müller,et al.  The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. , 1995, Advanced drug delivery reviews.

[5]  J. Forrest,et al.  Anomalous thermal denaturing of proteins adsorbed to nanoparticles , 2006, The European physical journal. E, Soft matter.

[6]  J. Kreuter,et al.  Nanoparticulate systems for brain delivery of drugs. , 2001 .

[7]  Sudipta Seal,et al.  Protein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potential. , 2007, Biomaterials.

[8]  P Couvreur,et al.  Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. , 1999, Biomaterials.

[9]  M. Lück,et al.  Plasma protein adsorption on biodegradable microspheres consisting of poly(D,L-lactide-co-glycolide), poly(L-lactide) or ABA triblock copolymers containing poly(oxyethylene). Influence of production method and polymer composition. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[10]  R. Müller,et al.  In vitro characterization of poly(methyl-methaerylate) nanoparticles and correlation to their in vivo fate , 1992 .

[11]  E. Gabellieri,et al.  Dendrimer-protein interactions studied by tryptophan room temperature phosphorescence. , 2006, Biochimica et biophysica acta.

[12]  Mitsuru Hashida,et al.  Fetuin mediates hepatic uptake of negatively charged nanoparticles via scavenger receptor. , 2007, International journal of pharmaceutics.

[13]  R. Müller,et al.  Influence of polysaccharide coating on the interactions of nanoparticles with biological systems. , 2006, Biomaterials.

[14]  J. McGrath,et al.  Binding between particles and proteins in extracts: implications for microrheology and toxicity. , 2005, Acta biomaterialia.

[15]  Patrick Soon-Shiong,et al.  Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  D. Hochstrasser,et al.  Colloidal carriers for intravenous drug targeting: Plasma protein adsorption patterns on surface‐modified latex particles evaluated by two‐dimensional polyacrylamide gel electrophoresis , 1993, Electrophoresis.

[17]  A. Malik,et al.  Albumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding protein. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[18]  W. Maechtle Analytical Ultracentrifugation of Polymers and Nanoparticles , 2006 .

[19]  R. Müller,et al.  'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. , 2000, Colloids and surfaces. B, Biointerfaces.

[20]  David Brown,et al.  The pulmonary toxicology of ultrafine particles. , 2002, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[21]  M. Foote Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel. , 2007, Biotechnology annual review.

[22]  R. Müller,et al.  Interactions of blood proteins with poly(isobutylcyanoacrylate) nanoparticles decorated with a polysaccharidic brush. , 2005, Biomaterials.

[23]  S. Davis,et al.  Innovations in avoiding particle clearance from blood by Kupffer cells: cause for reflection. , 1994, Critical reviews in therapeutic drug carrier systems.

[24]  Bengt-Harald Jonsson,et al.  Protein adsorption onto silica nanoparticles: conformational changes depend on the particles' curvature and the protein stability. , 2004, Langmuir : the ACS journal of surfaces and colloids.

[25]  R. Mahley,et al.  Plasma lipoproteins: apolipoprotein structure and function. , 1984, Journal of lipid research.

[26]  Malcolm L. H. Green,et al.  Complement activation and protein adsorption by carbon nanotubes. , 2006, Molecular immunology.

[27]  V. Torchilin,et al.  Biodegradable long-circulating polymeric nanospheres. , 1994, Science.

[28]  W. MacNee,et al.  Ultrafine (nanometre) particle mediated lung injury , 1998 .

[29]  Petra Krystek,et al.  Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. , 2008, Biomaterials.

[30]  R. Gurny,et al.  An investigation on the role of plasma and serum opsonins on the internalization of biodegradable poly(D,L-lactic acid) nanoparticles by human monocytes. , 1995, Life sciences.

[31]  R. Müller,et al.  Interactions of nanoparticles with body proteins--improvement of 2D-PAGE-analysis by internal standard. , 2000, International journal of pharmaceutics.

[32]  K. Donaldson,et al.  Inhalation of poorly soluble particles. II. Influence Of particle surface area on inflammation and clearance. , 2000, Inhalation toxicology.

[33]  R. Müller,et al.  Influence of Fluorescent Labelling of Polystyrene Particles on Phagocytic Uptake, Surface Hydrophobicity, and Plasma Protein Adsorption , 2004, Pharmaceutical Research.

[34]  David D. Christ,et al.  Chapter 33. Plasma Protein Binding of Drugs , 1996 .

[35]  R. Kane,et al.  Directed assembly of carbon nanotubes at liquid-liquid interfaces: nanoscale conveyors for interfacial biocatalysis. , 2006, Journal of the American Chemical Society.

[36]  H. Kurz,et al.  Evaluation of methods to determine protein-binding of drugs. Equilibrium dialysis, ultrafiltration, ultracentrifugation, gel filtration. , 1977, Arzneimittel-Forschung.

[37]  S M Moghimi,et al.  Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. , 2000, Trends in biotechnology.

[38]  R. Müller,et al.  Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparison of plasma protein adsorption patterns , 2005, Journal of drug targeting.

[39]  J. Klein Probing the interactions of proteins and nanoparticles , 2007, Proceedings of the National Academy of Sciences.

[40]  J. Kreuter,et al.  Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[41]  Mansoor M. Amiji,et al.  Nanotechnology for Cancer Therapy , 2006 .

[42]  D. Meijer,et al.  Molecular Mechanisms of the Adsorption of a Model Protein (Human Serum Albumin) on Poly(Methylidene Malonate 2.1.2) Nanoparticles , 2004, Pharmaceutical Research.

[43]  Patrick Couvreur,et al.  Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. , 2007, Biomacromolecules.

[44]  H M Patel,et al.  Serum opsonins and liposomes: their interaction and opsonophagocytosis. , 1992, Critical reviews in therapeutic drug carrier systems.

[45]  R. Müller,et al.  Plasma protein adsorption of Tween 80- and poloxamer 188-stabilized solid lipid nanoparticles. , 2003, Journal of drug targeting.

[46]  M. Frank,et al.  The role of complement in inflammation and phagocytosis. , 1991, Immunology today.

[47]  R. Müller,et al.  Influence of surface charge density on protein adsorption on polymeric nanoparticles: analysis by two-dimensional electrophoresis. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[48]  F. Zsila,et al.  Selective plasma protein binding of antimalarial drugs to alpha1-acid glycoprotein. , 2008, Bioorganic & medicinal chemistry.

[49]  V. Kolb-Bachofen,et al.  Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. , 1993, Biochimica et biophysica acta.

[50]  E. Blomberg,et al.  Probing protein adsorption onto mercaptoundecanoic acid stabilized gold nanoparticles and surfaces by quartz crystal microbalance and zeta-potential measurements. , 2007, Langmuir : the ACS journal of surfaces and colloids.

[51]  E. Schacht,et al.  In vitro displacement by rat serum of adsorbed radiolabeled poloxamer and poloxamine copolymers from model and biodegradable nanospheres. , 1998, Journal of pharmaceutical sciences.

[52]  L. Illum,et al.  Influence of block copolymers on the adsorption of plasma proteins to microspheres. , 1993, Biomaterials.

[53]  Patrick Soon-Shiong,et al.  Protein nanoparticles as drug carriers in clinical medicine. , 2008, Advanced drug delivery reviews.

[54]  Parag Aggarwal,et al.  Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. , 2009, Nanomedicine : nanotechnology, biology, and medicine.

[55]  R. Müller,et al.  Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption. , 2000, International journal of pharmaceutics.

[56]  A. Malik,et al.  Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function , 2002, Histochemistry and Cell Biology.

[57]  Sara Linse,et al.  Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles , 2007, Proceedings of the National Academy of Sciences.

[58]  Antonio Turiel,et al.  Nanoparticle-mediated local and remote manipulation of protein aggregation. , 2006, Nano letters.

[59]  H. Kiwada,et al.  Studies on the uptake mechanism of liposomes by perfused rat liver. II. An indispensable factor for liver uptake in serum. , 1987, Chemical and pharmaceutical bulletin.

[60]  Y. Michotte,et al.  The use of microdialysis for the determination of plasma protein binding of drugs. , 1992, Journal of pharmaceutical and biomedical analysis.

[61]  Michael J Banker,et al.  Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. , 2003, Journal of pharmaceutical sciences.

[62]  D. Tyrrell,et al.  The effect of serum protein fractions on liposome-cell interactions in cultured cells and the perfused rat liver. , 1977, Biochimica et biophysica acta.

[63]  M. Dobrovolskaia,et al.  Preclinical Characterization of Engineered Nanoparticles Intended for Cancer Therapeutics , 2006 .

[64]  Moghimi,et al.  Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system - The concept of tissue specificity. , 1998, Advanced drug delivery reviews.

[65]  A. Malik,et al.  Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[66]  S. Radford,et al.  Nucleation of protein fibrillation by nanoparticles , 2007, Proceedings of the National Academy of Sciences.

[67]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[68]  K. Higaki,et al.  Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. , 2007, International journal of pharmaceutics.

[69]  Lawrence Tamarkin,et al.  Colloidal Gold: A Novel Nanoparticle Vector for Tumor Directed Drug Delivery , 2004, Drug delivery.

[70]  A. Zahr,et al.  Macrophage uptake of core-shell nanoparticles surface modified with poly(ethylene glycol). , 2006, Langmuir : the ACS journal of surfaces and colloids.

[71]  L. Låstbom,et al.  Experimental and calculated parameters on particle phagocytosis by alveolar macrophages. , 2002, Journal of applied physiology.

[72]  M. Eriksson,et al.  Studies of drug binding to plasma proteins using a variant of equilibrium dialysis. , 2005, Journal of Pharmaceutical and Biomedical Analysis.

[73]  Robert Gelein,et al.  Role of the alveolar macrophage in lung injury: studies with ultrafine particles. , 1992 .

[74]  D. A. Kharkevich,et al.  Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. , 1998, Journal of microencapsulation.

[75]  Arezou A Ghazani,et al.  Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. , 2006, Nano letters.

[76]  P. Predki,et al.  Identification of small molecule targets on functional protein microarrays. , 2007, Methods in molecular biology.

[77]  L. Balant,et al.  Kinetics of blood component adsorption on poly(D,L-lactic acid) nanoparticles: evidence of complement C3 component involvement. , 1997, Journal of biomedical materials research.

[78]  R. Müller,et al.  Protein adsorption patterns on poloxamer- and poloxamine-stabilized solid lipid nanoparticles (SLN). , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[79]  S. K. Sundaram,et al.  Adsorbed proteins influence the biological activity and molecular targeting of nanomaterials. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[80]  Dzmitry G. Shcharbin,et al.  Effect of dendrimers on pure acetylcholinesterase activity and structure. , 2006, Bioelectrochemistry.

[81]  L. Vroman,et al.  Interaction of high molecular weight kininogen, factor XII, and fibrinogen in plasma at interfaces. , 1980, Blood.

[82]  L. Illum,et al.  Human serum albumin as a probe for surface conditioning (opsonization) of block copolymer-coated microspheres. , 1992, Biomaterials.

[83]  W. Semmler,et al.  Determination of Plasma Protein Adsorption on Magnetic Iron Oxides: Sample Preparation , 1997, Pharmaceutical Research.

[84]  Scott E McNeil,et al.  Nanotechnology for the biologist , 2005, Journal of leukocyte biology.

[85]  M. Michaelis,et al.  Covalent Linkage of Apolipoprotein E to Albumin Nanoparticles Strongly Enhances Drug Transport into the Brain , 2006, Journal of Pharmacology and Experimental Therapeutics.

[86]  J. Pawliszyn,et al.  Determination of drug plasma protein binding by solid phase microextraction. , 2006, Journal of pharmaceutical sciences.

[87]  T. Laue Analytical Centrifugation: Equilibrium Approach , 1999, Current protocols in protein science.

[88]  K. Higaki,et al.  Pre-coating with serum albumin reduces receptor-mediated hepatic disposition of polystyrene nanosphere: implications for rational design of nanoparticles. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[89]  Ravi S Kane,et al.  The protein-nanomaterial interface. , 2006, Current opinion in biotechnology.

[90]  J. Kreuter,et al.  Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles) , 1995, Brain Research.

[91]  David Farrar,et al.  Surface tailoring for controlled protein adsorption: effect of topography at the nanometer scale and chemistry. , 2006, Journal of the American Chemical Society.

[92]  F. Ding,et al.  Impacts of the surface charge property on protein adsorption on hydroxyapatite , 2002 .

[93]  Ravi S Kane,et al.  Structure and function of enzymes adsorbed onto single-walled carbon nanotubes. , 2004, Langmuir : the ACS journal of surfaces and colloids.

[94]  David M. Brown,et al.  Size-dependent proinflammatory effects of ultrafine polystyrene particles: a role for surface area and oxidative stress in the enhanced activity of ultrafines. , 2001, Toxicology and applied pharmacology.

[95]  Yu-Chi Wang,et al.  The sorption of lysozyme and ribonuclease onto ferromagnetic nickel powder 2. Desorption and competitive adsorption , 1995 .

[96]  M. Poznansky,et al.  Biological approaches to the controlled delivery of drugs: a critical review. , 1984, Pharmacological reviews.

[97]  D. Tomalia,et al.  Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. , 2007, Biochemical Society transactions.

[98]  S. Maiti,et al.  Spontaneous formation of a protein corona prevents the loss of quantum dot fluorescence in physiological buffers , 2007 .

[99]  Sara Linse,et al.  The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. , 2007, Advances in colloid and interface science.

[100]  J Szebeni,et al.  Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. , 2003, Progress in lipid research.

[101]  Peter Ramge,et al.  Apolipoprotein-mediated Transport of Nanoparticle-bound Drugs Across the Blood-Brain Barrier , 2002, Journal of drug targeting.

[102]  Hong-Zhuan Chen,et al.  In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[103]  P. Couvreur,et al.  Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[104]  J. Krieglstein,et al.  Zur Plasmaproteinbindung von Arzneimitteln , 1969, Klinische Wochenschrift.

[105]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[106]  Dzmitry G. Shcharbin,et al.  Dendrimer Interactions with Hydrophobic Fluorescent Probes and Human Serum Albumin , 2005, Journal of Fluorescence.

[107]  D. Fischer,et al.  Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[108]  R. Müller,et al.  Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. , 2005, International journal of pharmaceutics.

[109]  Joseph D. Andrade,et al.  Protein—surface interactions in the presence of polyethylene oxide , 1991 .

[110]  O. Olsson,et al.  140 mouse brain proteins identified by Ca2+-calmodulin affinity chromatography and tandem mass spectrometry. , 2006, Journal of proteome research.

[111]  K. Avgoustakis,et al.  Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. , 2001, International journal of pharmaceutics.

[112]  Sara Linse,et al.  Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. , 2007, Angewandte Chemie.

[113]  R. Müller,et al.  Adsorption kinetics of plasma proteins on oil-in-water emulsions for parenteral nutrition. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[114]  Kenneth A. Dawson,et al.  Protein–Nanoparticle Interactions , 2008, Nano-Enabled Medical Applications.

[115]  S. Sant,et al.  Effect of polymer architecture on surface properties, plasma protein adsorption, and cellular interactions of pegylated nanoparticles. , 2008, Journal of biomedical materials research. Part A.

[116]  J. Diederichs,et al.  Plasma protein adsorption patterns on liposomes: Establishment of analytical procedure , 1996, Electrophoresis.

[117]  Ravi S Kane,et al.  Increasing protein stability through control of the nanoscale environment. , 2006, Langmuir : the ACS journal of surfaces and colloids.

[118]  I. Kariv,et al.  Development of a high throughput equilibrium dialysis method. , 2001, Journal of pharmaceutical sciences.

[119]  D. A. Kharkevich,et al.  Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles , 1995 .

[120]  R. Müller,et al.  Particle size, surface hydrophobicity and interaction with serum of parenteral fat emulsions and model drug carriers as parameters related to RES uptake. , 1992, Clinical nutrition.

[121]  John E. Coligan,et al.  Current Protocols in Protein Science , 1996 .

[122]  Rainer H Müller,et al.  Functional groups on polystyrene model nanoparticles: influence on protein adsorption. , 2003, Journal of biomedical materials research. Part A.

[123]  K. Geiger,et al.  Chemotherapy of glioblastoma in rats using doxorubicin‐loaded nanoparticles , 2004, International journal of cancer.

[124]  M. Lück,et al.  Analysis of plasma protein adsorption on polymeric nanoparticles with different surface characteristics. , 1998, Journal of biomedical materials research.

[125]  Robert Gurny,et al.  Bioadhesion: Possibilities and Future Trends , 1990 .

[126]  M. Bryszewska,et al.  The effect of polyamidoamine dendrimers on human erythrocyte membrane acetylcholinesterase activity. , 2004, Bioelectrochemistry.

[127]  Jonathan S Dordick,et al.  Silica nanoparticle size influences the structure and enzymatic activity of adsorbed lysozyme. , 2004, Langmuir : the ACS journal of surfaces and colloids.

[128]  R. Müller,et al.  The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer--poloxamine 908. , 1987, Life sciences.

[129]  S. Moghimi,et al.  Capture of stealth nanoparticles by the body's defences. , 2001, Critical reviews in therapeutic drug carrier systems.

[130]  P. Couvreur,et al.  Analysis of plasma protein adsorption onto PEGylated nanoparticles by complementary methods: 2‐DE, CE and Protein Lab‐on‐chip® system , 2007, Electrophoresis.

[131]  Parag Aggarwal,et al.  Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. , 2008, Molecular pharmaceutics.

[132]  R. Kato,et al.  Studies on the mechanism of nitro reduction by rat liver. , 1969, Molecular pharmacology.

[133]  J. Kreuter,et al.  Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles , 1999, Pharmaceutical Research.